Open AccessMedicine

S. Faria, P. C. Fernandes, M. Silva, V. Lima, W. Fontes, R. Freitas‐Júnior, A. K. Eterovic, P. Forget

2016.12.12eCancerMedicalScience

DOI: 10.3332/ecancer.2016.702

tlooto Summary

The possibilities and limitations of using the neutrophil-to-lymphocyte ratio as a clinical tool for risk stratification helpful for individual treatment of breast cancer patients are addressed.

Abstract

Cellular-mediated inflammatory response, lymphocytes, neutrophils, and monocytes are increasingly being recognised as having an important role in tumorigenesis and carcinogenesis. In this context, studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) can be used as an independent prognostic factor in a variety of cancers. Particularly in breast cancer, several studies have shown that a high NLR is associated with shorter survival. Because the NLR can be easily determined from the full blood count, it could potentially provide a simple and inexpensive test cancer prognosis. This review addresses the possibilities and limitations of using the NLR as a clinical tool for risk stratification helpful for individual treatment of breast cancer patients. The potential underlying phenomena and some perspectives are discussed.

Citation format

FARIA, S., et al. The neutrophil-to-lymphocyte ratio: A narrative review. eCancerMedicalScience, 2016, 10.